StiRx Inc


Biotechnology company focused on development of vaccines and biologic therapeutics to prevent and treat sexually transmitted infections (STIs). The organization’s stated mission is to reduce STI-related morbidity and mortality and to develop alternatives to antibiotics by advancing vaccine candidates and antibody-based biologics against pathogens such as Neisseria gonorrhoeae and Chlamydia spp.

Industries

N/A


Products

Long-acting monoclonal antibody candidate for gonorrhea (early-stage)

Preclinical development of a long-acting monoclonal antibody intended for treatment and immuno‑prophylaxis against gonococcal infection.

Gonococcal vaccine candidate (early-stage)

Preclinical vaccine candidate targeting Neisseria gonorrhoeae intended to prevent infection in at‑risk populations.

Bispecific antibody candidate for chlamydia (early-stage)

Preclinical bispecific antibody program directed at Chlamydia species with exploratory development for other STI treatments.


Services

Research collaborations and partnerships

Collaborative research agreements and memoranda of understanding with external institutes to advance biologic therapeutics for STIs.

Scientific presentations and publications

Preparation and dissemination of research results through conference presentations and peer-reviewed articles.

Expertise Areas

  • Vaccine development for sexually transmitted infections
  • Monoclonal and bispecific antibody therapeutics
  • Preclinical biologics pipeline management
  • Infectious disease immunotherapeutics
  • Show More (2)

Key Technologies

  • Monoclonal antibody therapeutics
  • Bispecific antibodies
  • Vaccine platforms for bacterial STIs
  • Long-acting biologic formulations
  • Show More (1)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.